Weighing benefit-risk of medicines: Concepts and approaches

Drug Discovery Today: Technologies

Volumn 8, Issue 1, 2011, Pages

  Mt Isa, Shahrul ^a   Tzoulaki, Ioanna ^a,b   Callréus, Torbjörn ^c   Micaleff, Alain ^d   Ashby, Deborah ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF IOANNINA   (Greece)

^c DANISH MEDICINES AGENCY   (Denmark)

^d MERCK SERONO S A   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RIZATRIPTAN; SUMATRIPTAN; TRASTUZUMAB;

ASTHENIA; BREAST CANCER; CANCER HORMONE THERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL DECISION MAKING; CONCEPTUAL FRAMEWORK; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DRUG SAFETY; EARLY CANCER; FATIGUE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MIGRAINE; PATIENT COMPLIANCE; PATIENT DECISION MAKING; REVIEW; RISK BENEFIT ANALYSIS; SOMNOLENCE; STATISTICAL MODEL; THORAX PAIN;

EID: 80054998710     PISSN: None     EISSN: 17406749     Source Type: Journal    
DOI: 10.1016/j.ddtec.2011.04.002     Document Type: Review

References (22)

1. European Medicines Agency. (2006) Scientific discussion on Herceptin. (Report EMEA/H/C/278/II/0026)
2. Ashby, D. and Smith, A.F. (2000) Evidence-based medicine as Bayesian decision-making. Stat. Med. 19, 3291-3305
3. Medicines and Healthcare Regulatory Agency. (2007) Hormonereplacement therapy: safety update. (Report MHRA/2032228)
4. Mussen, F. et al. (2009) Development and application of a benefit-risk assessment model based on multi-criteria decision analysis. In Benefit-Risk Appraisal of Medicines. John Wiley & Sons, Ltd pp. 111-149
5. Medicines Evaluation Board, (1999) Public Assessment Report of the Medicines Evaluation Board for Maxalt.
6. Guo, J.J. et al. (2010) A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy - report of the ISPOR risk-benefit management working group. Value Health 13, 657-666
7. Phillips, L.D. et al. (2010) Benefit-Risk Methodology Project Work Package 2 Report: Applicability of Current Tools and Processes for Regulatory Benefit-Risk Assessment. European Medicines Agency (Report EMA/549682/2010)
8. Mussen, F. et al. (2009) Review of the current benefit-risk assessment models. In Benefit-Risk Appraisal of Medicines. John Wiley & Sons, Ltd pp. 63-97
9. Laupacis, A. et al. (1988) An assessment of clinically useful measures of the consequences of treatment. N. Engl. J. Med. 318, 1728-1733
10. Schulzer, M. and Mancini, G.B. (1996) 'Unqualified success' and 'unmitigated failure': number-needed-to-treat-related concepts for assessing treatment efficacy in the presence of treatment-induced adverse events. Int. J. Epidemiol. 25, 704-712 (Pubitemid 26290051)
11. Guyatt, G.H. et al. (1995) Users' guides to the medical literature. IX. A method for grading health care recommendations. Evidence-Based Medicine Working Group. JAMA 274, 1800-1804
12. Holden, W.L. et al. (2003) Benefit-risk analysis: a proposal using quantitative methods. Pharmacoepidemiol. Drug Saf. 12, 611-616 (Pubitemid 37220648)
13. Hutton, J.L. (2000) Number needed to treat: properties and problems. J. Roy. Stat. Soc. Ser. A 163, 403-415
14. Minelli, C. et al. (2004) Benefits and harms associated with hormone replacement therapy: clinical decision analysis. BMJ 328, 371
15. van Staa, T.P. et al. (2008) Individualizing the risks and benefits of postmenopausal hormone therapy. Menopause 15, 374-381 (Pubitemid 351355003)
16. Mussen, F. et al. (2009) Defining a systematic approach to decision making. In Benefit-Risk Appraisal of Medicines. John Wiley & Sons Ltd pp. 99-109
17. Belton, V. and Stewart, T.J. (2002) Multiple Criteria Decision Analysis: An Integrated Approach. Springer
18. Dodgson, J. et al. (2009) Multi-criteria Analysis: A Manual. Department for Communities and Local Government
19. The Committee for Medicinal Products for Human Use, (2008) Reflection Paper on Benefit-Risk Assessment Methods in the Context of the Evaluation of Marketing Authorisation Applications of Medicinal Products for Human Use. (Report EMEA/CHMP/15404/2007)
20. Coplan, P.M. et al. (2011) Development of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicines. Clin. Pharmacol. Ther. 89, 312-315
21. Garrison, L.P. et al. (2007) Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis. Health Aff. (Millwood) 26, 684-695
22. Keeney, R.L. and Raiffa, H. (1976) Decisions With Multiple Objectives: Preference and Value Tradeoffs. John Wiley